vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $321.2M, roughly 1.1× ALBANY INTERNATIONAL CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs 4.3%, a 8.9% gap on every dollar of revenue. On growth, ALBANY INTERNATIONAL CORP posted the faster year-over-year revenue change (12.0% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $51.4M). Over the past eight quarters, ALBANY INTERNATIONAL CORP's revenue compounded faster (1.2% CAGR vs 0.4%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
AIN vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $339.0M |
| Net Profit | $13.9M | $44.7M |
| Gross Margin | 31.1% | 59.7% |
| Operating Margin | 9.3% | 19.9% |
| Net Margin | 4.3% | 13.2% |
| Revenue YoY | 12.0% | -2.7% |
| Net Profit YoY | -21.5% | 19.3% |
| EPS (diluted) | $0.56 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.2M | $339.0M | ||
| Q3 25 | $261.4M | $327.3M | ||
| Q2 25 | $311.4M | $321.4M | ||
| Q1 25 | $288.8M | $330.6M | ||
| Q4 24 | $286.9M | $348.5M | ||
| Q3 24 | $298.4M | $345.5M | ||
| Q2 24 | $332.0M | $336.2M | ||
| Q1 24 | $313.3M | — |
| Q4 25 | $13.9M | $44.7M | ||
| Q3 25 | $-97.8M | $38.7M | ||
| Q2 25 | $9.2M | $34.0M | ||
| Q1 25 | $17.4M | $58.0M | ||
| Q4 24 | $17.7M | $37.5M | ||
| Q3 24 | $18.0M | $33.8M | ||
| Q2 24 | $24.6M | $38.4M | ||
| Q1 24 | $27.3M | — |
| Q4 25 | 31.1% | 59.7% | ||
| Q3 25 | -19.1% | 59.5% | ||
| Q2 25 | 31.3% | 59.8% | ||
| Q1 25 | 33.4% | 58.4% | ||
| Q4 24 | 31.5% | 55.5% | ||
| Q3 24 | 30.3% | 54.2% | ||
| Q2 24 | 33.9% | 52.0% | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 9.3% | 19.9% | ||
| Q3 25 | -44.6% | 17.9% | ||
| Q2 25 | 7.2% | 16.8% | ||
| Q1 25 | 9.8% | 21.6% | ||
| Q4 24 | 8.5% | 16.9% | ||
| Q3 24 | 8.4% | 15.0% | ||
| Q2 24 | 12.9% | 11.8% | ||
| Q1 24 | 12.4% | — |
| Q4 25 | 4.3% | 13.2% | ||
| Q3 25 | -37.4% | 11.8% | ||
| Q2 25 | 2.9% | 10.6% | ||
| Q1 25 | 6.0% | 17.5% | ||
| Q4 24 | 6.2% | 10.8% | ||
| Q3 24 | 6.0% | 9.8% | ||
| Q2 24 | 7.4% | 11.4% | ||
| Q1 24 | 8.7% | — |
| Q4 25 | $0.56 | $0.95 | ||
| Q3 25 | $-3.37 | $0.81 | ||
| Q2 25 | $0.31 | $0.70 | ||
| Q1 25 | $0.56 | $1.17 | ||
| Q4 24 | $0.57 | $0.74 | ||
| Q3 24 | $0.57 | $0.66 | ||
| Q2 24 | $0.79 | $0.74 | ||
| Q1 24 | $0.87 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $363.4M |
| Total DebtLower is stronger | $455.7M | $1.2B |
| Stockholders' EquityBook value | $726.2M | $911.5M |
| Total Assets | $1.7B | $2.5B |
| Debt / EquityLower = less leverage | 0.63× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $112.3M | $363.4M | ||
| Q3 25 | $108.3M | $296.4M | ||
| Q2 25 | $106.7M | $292.9M | ||
| Q1 25 | $119.4M | $306.8M | ||
| Q4 24 | $115.3M | $320.8M | ||
| Q3 24 | $127.2M | $299.3M | ||
| Q2 24 | $116.4M | $344.4M | ||
| Q1 24 | $125.4M | — |
| Q4 25 | $455.7M | $1.2B | ||
| Q3 25 | $480.6M | $1.2B | ||
| Q2 25 | $444.7M | $1.2B | ||
| Q1 25 | $416.4M | $1.2B | ||
| Q4 24 | $318.5M | — | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — | ||
| Q1 24 | $439.1M | — |
| Q4 25 | $726.2M | $911.5M | ||
| Q3 25 | $739.3M | $849.2M | ||
| Q2 25 | $888.6M | $882.3M | ||
| Q1 25 | $900.0M | $820.8M | ||
| Q4 24 | $943.5M | $906.9M | ||
| Q3 24 | $991.0M | $878.9M | ||
| Q2 24 | $967.5M | $905.4M | ||
| Q1 24 | $967.5M | — |
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.7B | $2.5B | ||
| Q1 25 | $1.7B | $2.5B | ||
| Q4 24 | $1.6B | $2.5B | ||
| Q3 24 | $1.8B | $2.5B | ||
| Q2 24 | $1.8B | $2.5B | ||
| Q1 24 | $1.8B | — |
| Q4 25 | 0.63× | 1.34× | ||
| Q3 25 | 0.65× | 1.44× | ||
| Q2 25 | 0.50× | 1.39× | ||
| Q1 25 | 0.46× | 1.49× | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | $93.6M |
| Free Cash FlowOCF − Capex | $51.4M | $87.2M |
| FCF MarginFCF / Revenue | 16.0% | 25.7% |
| Capex IntensityCapex / Revenue | 6.9% | 1.9% |
| Cash ConversionOCF / Net Profit | 5.31× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.7M | $93.6M | ||
| Q3 25 | $43.9M | $111.3M | ||
| Q2 25 | $32.7M | $17.4M | ||
| Q1 25 | $2.1M | $116.6M | ||
| Q4 24 | $78.5M | $43.8M | ||
| Q3 24 | $47.0M | $48.8M | ||
| Q2 24 | $83.4M | $-27.4M | ||
| Q1 24 | $9.6M | — |
| Q4 25 | $51.4M | $87.2M | ||
| Q3 25 | $25.9M | $106.3M | ||
| Q2 25 | $18.8M | $13.6M | ||
| Q1 25 | $-13.5M | $100.9M | ||
| Q4 24 | $60.2M | $35.2M | ||
| Q3 24 | $31.6M | $39.4M | ||
| Q2 24 | $63.6M | $-33.1M | ||
| Q1 24 | $-17.3M | — |
| Q4 25 | 16.0% | 25.7% | ||
| Q3 25 | 9.9% | 32.5% | ||
| Q2 25 | 6.0% | 4.2% | ||
| Q1 25 | -4.7% | 30.5% | ||
| Q4 24 | 21.0% | 10.1% | ||
| Q3 24 | 10.6% | 11.4% | ||
| Q2 24 | 19.2% | -9.8% | ||
| Q1 24 | -5.5% | — |
| Q4 25 | 6.9% | 1.9% | ||
| Q3 25 | 6.9% | 1.5% | ||
| Q2 25 | 4.5% | 1.2% | ||
| Q1 25 | 5.4% | 4.7% | ||
| Q4 24 | 6.4% | 2.5% | ||
| Q3 24 | 5.2% | 2.7% | ||
| Q2 24 | 6.0% | 1.7% | ||
| Q1 24 | 8.6% | — |
| Q4 25 | 5.31× | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | 3.56× | 0.51× | ||
| Q1 25 | 0.12× | 2.01× | ||
| Q4 24 | 4.44× | 1.17× | ||
| Q3 24 | 2.61× | 1.44× | ||
| Q2 24 | 3.39× | -0.71× | ||
| Q1 24 | 0.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
